Efficacy of micafungin alone or in combination against systemic murine aspergillosis.
We tested the efficacy of micafungin (FK) alone or in combination with other antifungals against systemic murine aspergillosis. FK alone at 10 mg/kg of body weight/dose prolonged survival (P = 0.01) and reduced CFU in the brain and kidney. Combination therapy that used suboptimal FK with amphotericin B or itraconazole prolonged survival. Although no survivors were free of infection, no antagonism was seen. Nikkomycin Z with FK showed significantly greater potency (P < 0.01) than either alone.
Luque
Javier Capilla
JC
University of Rovira i Virgili, Reus, Spain.
Clemons
Karl V
KV
Stevens
David A
DA
D000666:Amphotericin B / Q000008:administration & dosage; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D054714:Echinocandins; D005260:Female; D017964:Itraconazole / Q000008:administration & dosage; D055666:Lipopeptides; D008074:Lipoproteins / Q000008:administration & dosage / Q000627:therapeutic use*; D000077551:Micafungin; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000627:therapeutic use*
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D017964:Itraconazole; D000666:Amphotericin B; D000077551:Micafungin